Turna Ray

The company believes the platform will expedite its longstanding goal of amassing genomic and other information from patients through their lifespan to fuel discoveries and improve care.

Researchers investigated the potential of liquid biopsy testing to help patients avoid endocrine resistance in the PADA-1 trial and identify best responders in the BioltaLEE trial.

Researchers analyzed data from Syapse's Learning Health Network and found that more Black patients were unable to be tested or declined it compared to white patients.

A large, randomized trial exploring the benefit of adding chemo to endocrine therapy for premenopausal women with Oncotype DX scores of 0 to 25 will likely be needed.

The company plans to launch a polygenic risk score, a germline-somatic test platform, and LDT and kitted tests for disease monitoring and therapy selection.

National Government Services' proposal to broaden coverage of large sequencing panels for solid tumor patients is positive but may need clarification to ensure appropriate patient care.

The EC has stuck with its timeline to implement the new regulations in eight months, raising concerns for cancer patients' ability to receive biomarker testing and treatments.

The law requires state employee, Medicaid, public school, and small employer plans to cover evidence-based biomarker testing, a change that will readily impact cancer patients.

Researchers used real-world data to identify low NGS testing rates, particularly among Black patients, suggesting many aren't getting precision medical treatment.

At ASCO, the company detailed its efforts to make the 93-SNP riskScore, which it plans to offer as a standalone DTC test next year, relevant for women of all ancestries.